Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 225 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 225 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Potassium is the principal intracellular cation; it restores normal potassium levels, essential for nerve conduction, muscle contraction, and acid-base balance. Dextrose provides calories, and sodium chloride corrects electrolyte deficits; the combination maintains osmotic pressure.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
10-40 mEq potassium chloride in 1000 mL D5 0.225% NaCl, intravenous infusion at a rate not exceeding 10 mEq/hour and 200 mEq/24 hours.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Potassium has no true terminal half-life as it is homeostatically regulated; the plasma disappearance half-life after IV administration is approximately 1-2 hours, reflecting rapid cellular uptake, but steady-state redistribution in total body stores takes days.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal: >90% excreted unchanged in urine; minimal biliary/fecal elimination (<5%).
Category C
Category A/B
Electrolyte
Electrolyte